| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Glenmark Life Sciences Limited (NSE: GLS)
GLS Technical Analysis
4
| As on 3rd May 2024 GLS SHARE Price closed @ 829.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 684.18 & Buy for SHORT-TERM with Stoploss of 809.42 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GLSSHARE Price
| Open | 841.50 | Change | Price | % |
| High | 848.00 | 1 Day | -11.20 | -1.33 |
| Low | 819.00 | 1 Week | 15.00 | 1.84 |
| Close | 829.95 | 1 Month | 32.95 | 4.13 |
| Volume | 77779 | 1 Year | 320.90 | 63.04 |
| 52 Week High 671.55 | 52 Week Low 374.55 | ||||
NSE INDIA Most Active Stocks
| YESBANK | 24.95 | -1.96% |
| IDEA | 13.20 | 0.00% |
| BHEL | 305.00 | 4.20% |
| NHPC | 99.25 | 1.28% |
| GTLINFRA | 1.75 | 0.00% |
| IFCI | 52.50 | 4.90% |
| RTNPOWER | 9.50 | 3.83% |
| SAIL | 167.95 | 1.51% |
| TATASTEEL | 166.50 | -0.51% |
| PNB | 135.80 | -1.63% |
NSE INDIA Top Gainers Stocks
| RBL | 1021.40 | 20.00% |
| RBL | 1021.40 | 20.00% |
| PENINLAND | 58.60 | 19.96% |
| TFL | 13.85 | 19.91% |
| TFL | 13.85 | 19.91% |
| ARROWGREEN | 555.90 | 14.70% |
| TOKYOPLAST | 131.00 | 13.86% |
| AVTNPL | 98.95 | 11.05% |
| ORIENTHOT | 150.00 | 10.74% |
| UNIVASTU | 210.05 | 9.52% |
NSE INDIA Top Losers Stocks
| COFORGE | 4482.55 | -10.09% |
| VOLTAMP | 9983.05 | -8.81% |
| EIMCOELECO | 2127.60 | -8.07% |
| BLISSGVS | 119.05 | -8.00% |
| APTECHT | 239.15 | -7.56% |
| ARVSMART | 673.10 | -7.38% |
| GENESYS | 567.75 | -6.75% |
| GODHA | 0.70 | -6.67% |
| WILLAMAGOR | 37.15 | -6.66% |
| SILLYMONKS | 17.50 | -6.17% |
| GLS Daily Charts |
GLS Intraday Charts |
Whats New @ Bazaartrend |
GLS Free Analysis |
|
|
GLS Important Levels Intraday
| RESISTANCE | 885.83 |
| RESISTANCE | 867.91 |
| RESISTANCE | 856.83 |
| RESISTANCE | 845.76 |
| SUPPORT | 814.15 |
| SUPPORT | 803.07 |
| SUPPORT | 791.99 |
| SUPPORT | 774.07 |
GLS Target May 2024
| 4th UP Target | 1215.06 |
| 3rd UP Target | 1077.15 |
| 2nd UP Target | 991.91 |
| 1st UP Target | 906.67 |
| 1st DOWN Target | 663.43 |
| 2nd DOWN Target | 578.19 |
| 3rd DOWN Target | 492.95 |
| 4th DOWN Target | 355.04 |
GLS Weekly Target
| 4th UP Target | 1050.33 |
| 3rd UP Target | 974.84 |
| 2nd UP Target | 928.18 |
| 1st UP Target | 881.52 |
| 1st DOWN Target | 748.38 |
| 2nd DOWN Target | 701.72 |
| 3rd DOWN Target | 655.06 |
| 4th DOWN Target | 579.57 |
GLS Target2024
| 4th UP Target | 1244.79 |
| 3rd UP Target | 1056.3 |
| 2nd UP Target | 939.79 |
| 1st UP Target | 823.28 |
| 1st DOWN Target | 490.83 |
| 2nd DOWN Target | 374.32 |
| 3rd DOWN Target | 257.81 |
| 4th DOWN Target | 69.31 |
Glenmark Life Sciences Limited ( NSE INDIA Symbol : GLS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GLS Synopsis Technicals View
| 50 Day EMA |
N/A (Short Term) |
N/A | |
| 100 Day EMA | N/A (Mid Term) | N/A | |
| 200 Day EMA | N/A (Long Term) | N/A | |
| MACD (12 26 9) | N/A | N/A | |
| RSI (14) | N/A | N/A | |
| MFI (14) | N/A | N/A | |
| CCI (20) | N/A | N/A | |
| WILLIAM %R (14) | N/A | N/A | |
| ADX (14) | N/A | N/A | |
| PSAR | N/A | N/A | |
| 10 Day Avg Volume | N/A | ||
GLS Other Details
| Segment | EQ | |
| Market Capital | 77694156800.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
GLS Address
 |
||
GLS Latest News
GLS Business Profile
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service